title: Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review.
abstract: For patients with late-stage (metastatic) breast cancer, the impact of treatment on health-related quality of life is a key factor in decision-making. A systematic review was conducted to identify health state utility values (HSUVs) for late-stage breast cancer, derived using methods preferred by health technology assessment (HTA) agencies, by treatment line. The aim was to generate a list of HSUVs, that could help to justify the values used to populate cost-utility models. Areas covered: Ten electronic databases, international congress websites and online HSUV databases were searched (January 1995-May 2014) for HSUVs for adults with late-stage breast cancer that had been derived from methods favoured by HTA agencies. Publications were included only if they reported studies that originated HSUVs. Expert commentary: Large numbers of HSUVs are available for late-stage breast cancer in the published literature. Contrary to expectations, the HSUVs reported in the literature vary greatly for some health states. As a result, the choice of HSUV can have considerable implications for the outcomes of economic evaluations. Standardization of HSUV methodology is expected to reduce variability; however, further research is recommended for assessing the sensitivity of generic preference-based measures in late-stage (metastatic) breast cancer.
authors: a F Hoffmann-La Roche AG , MORSE Health Technology Assessment Group , Basel , Switzerland.
authors: Noman
authors: N
authors: Paracha
authors: a F Hoffmann-La Roche AG , MORSE Health Technology Assessment Group , Basel , Switzerland.
authors: Per-Olof
authors: PO
authors: Thuresson
authors: b Novartis Pharma AG , Market Access Oncology Region Europe , Basel , Switzerland.
authors: Santiago G
authors: SG
authors: Moreno
authors: c Epidemica Ltd. , Systematic Review Department , Bicester , UK.
authors: Katherine S
authors: KS
authors: MacGilchrist
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D003362:Cost-Benefit Analysis; D003657:Decision Making; D005260:Female; D006304:Health Status; D006801:Humans; D018803:Models, Economic; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011788:Quality of Life; D013673:Technology Assessment, Biomedical
keywords: Advanced breast cancer; cost–utility analysis; health state utility; health status; metastatic breast cancer; quality of life; quality of life index; quality-adjusted life-year; systematic review; treatment line